Symbols

TGTX

Tg Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TGTX

Tg Therapeutics, Inc.

A biopharmaceutical company that develops therapeutics for diseases caused by protien or gene dysfunction

Industry

Pharmaceutical

Established Date

Listing Date

05/30/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

399

Fiscal Year Ends

12-31

Website

www.tgtherapeutics.com

Security Type

Common stock

Office address

3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560

Business

Introduction

TG Therapeutics, Inc., was incorporated in Delaware in 1993. The company is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of new therapies for B cell-mediated diseases. Its product BRIUMVI (ublituximab-xiiy) has received regulatory approval in the US, EU and UK for the treatment of adult patients with relapsing multiple sclerosis.

Company Financials

EPS

TGTX has released its 2025 Q4 earnings. EPS was reported at 0.14, versus the expected 0.37, missing expectations. The chart below visualizes how TGTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TGTX has released its 2025 Q4 earnings report, with revenue of 192.57M, reflecting a YoY change of 78.00%, and net profit of 23.04M, showing a YoY change of -1.26%. The Sankey diagram below clearly presents TGTX's revenue sources and cost distribution.